DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six ...

With no single headline event driving DexCom (DXCM) recently, investors are watching the stock after a gain of about 21% over the past month and roughly 7% over the past 3 months. See our latest ...

DexCom is now rated a 'Buy' as improved fundamentals and a 15% lower stock price present a more attractive entry. Q1/26 results showed 15% revenue growth, and 90.9% operating income growth and raised ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...

At long last, Dexcom's Share app, which allows users to view and share data from their G5 continuous glucose monitors, will be available for Android users. The Android app just now received FDA ...